@article {8099,
	title = {Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer},
	journal = {Oncology},
	volume = {60},
	year = {2001},
	note = {Cited By :9Export Date: 21 February 2017},
	month = {2001},
	pages = {214 - 220},
	abstract = {Dose-dense sequential chemotherapy appears to be a promising approach in the management of patients with operable breast cancer. We evaluated the tolerability of such a novel chemotherapeutic regimen in high-risk patients. From February 1995 until September 1997, 49 women with histologically confirmed breast cancer and >=10 involved axillary nodes were treated postoperatively with three cycles of epirubicin (110 mg/m2) followed by three cycles of paclitaxel (250 mg/m2 in a 3-hour infusion) followed by three cycles of {\textquoteright}intensified{\textquoteright} CMF (cyclophosphamide 840 mg/m2, methotrexate 57 mg/m2, fluorouracil 840 mg/m2; E-T-CMF). All cycles were repeated every 2 weeks with G-CSF support. Ovarian ablation with monthly injections of triptorelin for 1 year was performed in premenopausal patients and tamoxifen was prescribed for 5 years to all women with positive receptor status after the completion of chemotherapy. A total of 456 cycles of chemotherapy were administered, 363 (80\%) of them at full dose. Forty-seven (96\%) patients received all 9 cycles of chemotherapy. Relative dose intensity of epirubicin was 0.98, of paclitaxel 0.97, of cyclophosphamide 0.99, of methotrexate 0.98 and of fluorouracil 0.99. Grade 3-4 toxicities included anemia (8\%), leukopenia (8\%), peripheral neuropathy (6\%), neutropenia (4\%), thrombocytopenia (4\%), stomatitis (2\%), diarrhea (2\%), fatigue (2\%) and hypersensitivity reaction (2\%). Febrile neutropenia occurred in 2 patients. Alopecia was universal. After a median follow-up of 3 years, 11 women (22\%) relapsed and 4 (8\%) died. The 3-year actuarial disease-free survival rate was 72\% and the 3-year overall survival rate 90\%. The E-T-CMF regimen is well tolerated, as adjuvant treatment, in patients with operable breast cancer with promising activity and deserves further evaluation in phase III studies. Copyright {\textcopyright} 2001 S. Karger AG, Basel.},
	keywords = {Anthracyclines, breast cancer, Chemotherapy, Paclitaxel},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-17744389183\&doi=10.1159\%2f000055321\&partnerID=40\&md5=38f8abb1cba703cefb242b784bac9f0e},
	author = {Fountzilas, G. and Papadimitriou, C. and Aravantinos, G. and Nicolaides, C. and Stathopoulos, G. and Bafaloukos, D. and Kalofonos, H. and Ekonomopoulos, T. and Skarlos, D. and N. Pavlidis and Dimopoulos, A.M.}
}
